Business Blockbuster - Helpng business to be more visible on Google

Business Daily Media


.

Galimedix Appoints Dr. Luciana Summo as Vice President, R&D Operations

  • Brings over 20 years of clinical experience, including management of Phase 1-2 clinical trials in a variety of indications such as ophthalmology
  • Will oversee all R&D operations with focus on clinical development and operations

Kensington, MD, USA - EQS Newswire - 25 October 2023 - Galimedix Therapeutics, Inc.

("Galimedix"), a Phase 2 clinical-stage biotechnology company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious eye and brain diseases, today announced the appointment of Luciana Summo, PhD, as Vice President, R&D Operations. In this newly created position, she will oversee all activities related to R&D operations, with an emphasis on clinical development and operations. This includes spearheading the design, planning, and execution of clinical trials. Dr. Summo reports to Hermann Russ, MD, PhD, Co-founder and Chief Scientific Officer.

"We are delighted to welcome Luciana to Galimedix," said Alexander Gebauer, MD, PhD, Co-founder and Executive Chairman. "She brings strong experience setting up and running clinical trials and ensuring that all of the proper support structures are put in place. As we move our lead product candidate, GAL-101, into Phase 2 testing for the treatment of dry age-related macular degeneration, her skill set is the perfect fit for this next stage in our development. Luciana will play a pivotal role in defining Galimedix's overall R&D strategy and driving our R&D initiatives forward. All of us very much look forward to working with her as we contribute to advancing innovative healthcare solutions that have the potential to improve the lives of patients."

Dr. Summo has over 20 years of experience in clinical development and operations, including the management of Phase 1-2 clinical trials in several indications such as ophthalmology, cardiology, and oncology. Prior to joining Galimedix, she worked in positions of increasing responsibility in the clinical departments at OMEICOS Therapeutics GmbH, NOXXON Pharma AG, and Berlin-Chemie AG/ Menarini Group. She is well versed in setting up and overseeing clinical trials on a global scale and has played a key role in transitioning programs from pre-clinical to clinical stage. She has experience with the entire spectrum of activities related to R&D operations, with a special emphasis on clinical development and clinical operations, including also quality management and CMC. She works closely with cross-functional teams, including CROs, scientists, clinicians, regulatory affairs specialists, and different stakeholders, to ensure that trials are conducted in accordance with rigorous scientific standards and regulatory guidelines. Dr. Summo has experience in submitting Clinical Trial Applications (CTAs) in Europe and Investigational New Drug (IND) applications in the US and prepared for and participated in pre-IND meetings with the US Food and Drug Administration (FDA), as well as regulatory agency meetings in Europe. She also has set up from scratch and run a clinical operations department.

Luciana Summo, PhD, Vice President, R&D Operations, added: "I am truly excited to be joining Galimedix at this important point in the Company's growth. The programs in ophthalmology and Alzheimer's disease have the potential to change the treatment paradigm, and I look forward to working with the rest of the team to bring them forward in the clinic."
Hashtag: #Galimedix

The issuer is solely responsible for the content of this announcement.

About Galimedix Therapeutics, Inc.

Galimedix is a Phase 2 clinical-stage private company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious eye and brain diseases. Founded by a seasoned and highly dedicated team of bio-entrepreneurs, pharmaceutical executives and scientists, Galimedix's groundbreaking small molecules offer the hope of changing the course of disease where amyloid beta (Aβ) plays a role, such as in dry age-related macular degeneration (AMD), glaucoma and Alzheimer's disease - Galimedix's initial areas of focus. The Company's approach targets toxic Aβ oligomers and protofibrils. Many studies have indicated that these oligomers and protofibrils are an underlying cause of neurodegenerative diseases of the eye. And, recent approvals and promising Phase 3 results of anti-Aβ drugs also have validated them as a key target in Alzheimer's disease. Compelling pre-clinical data support the potential of Galimedix's product candidates to slow or stop neurodegeneration and also restore lost neuronal function. A Phase 2 proof-of-concept study in dry AMD with lead program, topical GAL-101, is in preparation with strong support from partner, Théa Open Innovation (TOI). Clinical studies in other indications are planned.

News from Asia

XTransfer, VPBank and SmartPay Announce Partnership at Singapore FinTech Festival 2026

Empowering SMEs in Vietnam–China and Vietnam–ASEAN TradeSINGAPORE – Media OutReach Newswire – 19 November 2026 – XTransfer, the world's leading B2B cross-border trade payment platform, VPBank, a...

Columbia Asia Hospital Tebrau and Columbia Asia Hospital Iskandar Puteri jointly achieve Malaysia Book of Records recognition for their Mega Parenthood Workshop 2026

JOHOR BAHRU, MALAYSIA – Media OutReach Newswire – 19 November 2026 – Becoming a parent is one of life's most beautiful journeys, filled with excitement, questions and, at times, uncertainty. Recog...

Lambency Detailing becomes GTECHNIQ Accredited Detailer at both outlets and launches its new e-commerce website

Partnership brings GTECHNIQ’s accredited-only Crystal Serum Ultra to Ubi and Bukit Batok with a 10-year warranty; the new lambencydetailing.com launches the same day with online purchase and bookin...

Uthoppia House Founder Yusup Ngadimin Receives 2026 Spirit of Enterprise Start-up Award

Recognition marks a milestone in the Singapore AI company’s journey to help individuals and employers make more informed career and talent decisionsSINGAPORE– Media OutReach Newswire – 19 November...

UnionPay International Debuts Digital Trade Solution at CIIE 2026, Streamlining Cross-Border B2B Settlement for Global E-Commerce

SHANGHAI, CHINA – Media OutReach Newswire – 19 November 2026 — UnionPay International (UPI), together with Bank of China and Shanghai E&P International, today officially unveiled its Digital T...

DNA Brands Co Marks Fourth Anniversary, Building on Its Growth in Singapore’s Beauty and Wellness Industry

Celebrating four years of progress, the Singapore company looks to elevate its achievements through people, innovation and a shared passion for beauty and wellness as self-care becomes an increasin...

LittleLives, Little Lab and SEGi College Sign MOU to Explore Early Childhood Education Collaboration Across ASEAN

SUBANG JAYA, MALAYSIA - Media OutReach Newswire - 20 November 2026 – LittleLives, Little Lab and SEGi College signed a Memorandum of Understanding (MOU) on 5 November 2026 to explore collaboration...

Bosideng Marks 50 Years with ‘Warmth Code’ Exhibition in Shanghai

SHANGHAI, CHINA – Media OutReach Newswire – 20 November 2026 – Bosideng marked its 50th anniversary with 'Warmth Code: Half a Century of History', a landmark exhibition at Gate M West Bund Dream C...

Sixth Asia International Innovation and Invention Hong Kong Showcases Over 180 Innovations from the Asia-Pacific

Hong Kong Exporters’ Association’s “Hong Kong Innovation and Invention” Program exhibits at Entrepreneur Day for the fourth consecutive yearHONG KONG SAR – Media OutReach Newswire – 20 November 20...

Travel Insurance Was Built for the Few Who Claim. Ancileo’s Felt Coverage™ is for Everyone Else

There are now two kinds of travel insurance: coverage that’s contracted, and coverage that’s felt. Ancileo is the first to introduce the latter.SINGAPORE – Media OutReach Newswire – 20 November 20...

New Research Highlights What Australian Retailers Need to Deliver

New research among Australian SHEIN customers reveals how price comparisons, product quality and customer reviews are shaping purcha...

Why the secrecy around car insurance?

Every year, millions of Australians receive their car insurance renewal and promise themselves they’ll look at it properly later. Then life gets in ...

Australian workers spend almost an hour a day administering email

Research finds email filing, searching and rework consuming an estimated 58 minutes a day and potentially exposing organisations to millionsAustralian...

Customer Service Is Becoming Part of the Small Business Sales and Marketing Engine

For Customer Service Week, 5-9 October, Thryv is urging small businesses to look beyond generating  enquiries and examine what happens after a custome...

Gift Cards as the gateway to agentic payments

Prepaid and stored value gives consumers the trust and control to try AI shopping agents By Blackhawk Network VP Head of ANZ Kieran Nolan For deca...

Why Data Accumulation Without Governance Undermines Sustainability Goals

In July 2026, Group 2 entities, the second cohort of Australian businesses, began their first reporting period under the mandatory climate disclosur...